Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Apr 5, 2011


Fluidigm has appointed Evan Jones to its board of directors and its compensation committee. Jones is the managing member of jVen Capital, a life sciences-investment company. Prior to forming jVen Capital, he was co-founder, chairman, and CEO of Digene Corporation, a publicly traded biotechnology company focused on women's health and molecular-diagnostic testing.

He is currently executive chairman of OpGen, a genomics company focused in the areas of microbial genetics and DNA sequence analysis. He is director of CAS Medical Systems and Veracyte. He was chairman of Signature Genomic Laboratories from 2008 until the company was sold to Perkin-Elmer in May 2010.

Jones has a BA from the University of Colorado at Boulder and an MBA from the University of Pennsylvania's Wharton School.

Roche Diagnostics has appointed Robert Yates to head Roche Applied Science. He succeeds Manfred Baier, who will retire from the company at the end of the year. Yates will report to Roche Diagnostics COO Daniel ODay.

Most recently, Yates served as Roche Diagnostics' global head of business development and licensing. He has also held leadership positions in R&D, engineering and process management within Roche Diagnostics, both in the company's Indianapolis facility and in Roche's headquarters in Basel, Switzerland.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.